Prothrombin complex concentrate in trauma patients - 13/02/15
Abstract |
Background |
Despite recent advances, trauma care providers nowadays face a number of coagulopathic patients. Coagulopathy in trauma patients can be secondary to the traumatic insult or therapeutic effect of the anticoagulants including the Vitamin K antagonist. The efficacy of a concentrated product of Vitamin K–dependent coagulation factors, prothrombin complex concentrate (PCC), to reverse coagulopathy has been tested mainly in nontrauma setting.
Data Sources |
Currently available literature on the use of PCC was identified by searches of electronic database. The indications (trauma vs nontrauma) and types of the PCC products (3 vs 4 factors) were also reviewed in each article.
Conclusions |
There are small studies that show promising results regarding PCC use to reverse the Vitamin K antagonist–related coagulopathy in trauma patients. It remains unanswered whether PCC can be effective as an adjunct in patients who require massive transfusion.
Le texte complet de cet article est disponible en PDF.Keywords : Prothrombin complex concentrate, Trauma, Coagulopathy
Plan
All authors deny any potential conflicts of interest. No internal and external financial support was used for this study. |
Vol 209 - N° 2
P. 413-417 - février 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?